# US 2009/0275569 A1 · Benzotriazine Inhibitors of Kinases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0275569 A1
- Document ID: US20090275569A1
- Status: Published application
- Kind: A1
- Application number: 12/207,019
- Filed: 2008-09-09
- Published: 2009-11-05
- Earliest claimed: 2004-04-08
- Inventors: Xianchang Gong; Kathy Barrett; Jianguo Cao; Colleen Gritzen; Glenn Noronha; John D. Hood; Chi Ching Mak; Andrew McPherson; Ved Prakash Pathak; Joel Renick; Richard M. Soll; Ute Splittgerber; Wolfgang Wrasidlo; Ningning Zhao; Elena Dneprovskaia; Binqi Zeng; Glenn Noronha
- Web page: https://patentgrep.com/patent/US20090275569A1

## CPC

- C07D 253/08: condensed with carbocyclic rings or ring systems
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.

## Claims

### Claim 1

(canceled)

### Claim 2 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 3 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 4 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 5

(canceled)

### Claim 6 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 7 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 8 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 9

(canceled)

### Claim 10 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 11 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 12

(canceled)

### Claim 13 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 14 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 15 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 16 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 17 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 18 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 19 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 20 (depends on 21)

The method of claim 21, wherein the compound is selected from the group consisting of:

### Claim 21

A method for treating a disorder associated with compromised vasculostasis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by:
wherein each of A is independently selected from a group consisting of CH, N, NH, O, S, and a part of a ring fusion to form a second ring, where the second ring is an aromatic, a heteroaromatic, a bicyclic aromatic, a bicyclic aromatic heterocyclic ring, or a bicyclic with only the first ring being aromatic or heteroaromatic;
each of B is independently selected from a group consisting of CH, N, NH, O, S, and a part of a ring fusion to form a second ring, where the second ring is an aromatic, a heteroaromatic, a bicyclic aromatic, a bicyclic aromatic heterocyclic ring, or a bicyclic with only the first ring being aromatic or heteroaromatic;
R0 is selected from a group consisting of H and lower alkyl;
L is selected from a group consisting of a bond, and a substituted or unsubstituted alkyl, alkenyl, or alkynyl linking moiety;
R1 is selected from a group consisting of C(R′)3, OR′, N(R′)2, NR′C(O)R′, NR′C(O)O(R′), NR′C(O)N(R′)2, SR′, C(O)(O)R′, C(O), C(O)N(R′)2, SO3R′, OSO2R′, SO2R′, SOR′, S(O)N(R′)2, OS(O)(O)N(R′)2, S(O)(O)N(R′)2, PO4R′, OPO2R′, PO3R′, PO2R′, and a 3-6 membered heterocycle with one or more heterocyclic atoms with each heteroatom independently being capable of carrying any R′ group on it, wherein R′ is selected from a group consisting of hydrogen, lower alkyl, alkyl-hydroxyl, thiol-alkyl, alkyl-thiol, aminoalkyl, alkylamino, branched alkyl, branched alkyl hydroxyl, branched thio-alkyl, branched alkyl-thiol, branched aminoalkyl branched alkylamino, and a closed 3-6 membered carbocycle or heterocycle, with each heteroatom in the 3-6 membered heterocycle being capable of carrying any R′ group on it, and wherein each R′ is independent in case there is more than one R′;
R2 is a substituent situated at position 5, 6 or 8 of the ring, wherein R2 is selected from a group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, iso-pentyl, phenyl, substituted phenyl, halogen, branched or unbranched alkylamino, branched or unbranched aminoalkyl, branched or unbranched alkyloxo, branched or unbranched oxyalkyl, branched or unbranched thioalkyl, branched or unbranched alkylthiol CF3, sulfonamido, substituted sulfonamido, sulfonate, sulfonate ester, phosphate, phosphate ester, phosphonate, phosphonate ester, carboxo, amido, ureido, substituted carboxo, substituted amido, substituted ureido, or a 3-6 membered carbocycle or heterocycle attached to positions 5, 6 or 8 directly or through group L, each heteroatom independently being capable of carrying any group R2, with the further proviso that either one, two or three substituents R2 are present in the ring, each of the substituents R2 being the same or different;
R3 selected from a group consisting of hydrogen, alkyl, alkoxy, halogen, CF3, cyano, substituted alkyl, or hydroxyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, C(R″)3, OR″, N(R″)2, NR″C(O)R″, NR″C(O)NR″, R″, C(O)(O)R″, OC(O)R″, C(O)N(R″)2, C(O), OC(O)N(R″)2, SO3R″, OSO2R″, SO2R″, SOR″, PO4R″, OPO2R″, PO3R″, PO2R″, wherein R″ is hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, lower alkyl, branched lower alkyl, alkyl-hydroxyl, branched alkyl-hydroxyl, amino-alkyl, branched amino-alkyl, alkyl-amino, branched alkyl-amino, thiol-alkyl, branched thiol-alkyl, alkyl-thiol, branched thiol-alkyl, or may form a closed 3-6 membered heterocycle with one or more heterocyclic atoms, branched alkyl, branched alkyl hydroxyl, where each R″ is independent in case there is more than one R″;
n is an integer having the value between 1 and 5, with the further proviso that if n≧2, then each group R3 is independent of the other groups R3,
or a pharmaceutically acceptable salt, N-oxide, or an individual diastereomer thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the disorder is myocardial infarction, stroke, congestive heart failure, an ischemia or reperfusion injury, arthritis or other arthropathy, retinopathy or vitreoretinal disease, macular degeneration, vascular leakage syndrome, edema, transplant rejection, burn, or acute or adult respiratory distress syndrome (ARDS).

### Claim 23 (depends on 21)

The method of claim 21, wherein the disorder is vascular leakage syndrome (VLS).

### Claim 24

(canceled)

### Claim 25 (depends on 21)

The method of claim 21, wherein the disorder is a vitreoretinal disease.

### Claim 26 (depends on 21)

The method of claim 21, wherein the disorder is ARDS.

### Claim at position 27

27-28. (canceled)

### Claim 29 (depends on 21)

The method of claim 21, wherein the disorder is stroke.

### Claim 30 (depends on 21)

The method of claim 21, wherein the disorder is myocardial infarction.

### Claim 31 (depends on 21)

The method of claim 21, wherein the disorder is ischemia or reperfusion injury.

### Claim 32 (depends on 21)

The method of claim 21, wherein the disorder is arthritis.

### Claim 33 (depends on 21)

The method of claim 21, wherein the disorder is edema.

### Claim 34 (depends on 21)

The method of claim 21, wherein the disorder is transplant rejection.

### Claim 35

(canceled)

### Claim 36 (depends on 21)

The method of claim 21, wherein the disorder is congestive heart failure.

### Claim at position 36

37-58. (canceled)

### Claim 59 (depends on 21)

The method of claim 21, further comprising administering an anti-inflammatory agent, chemotherapeutic agent, immunomodulatory agent, therapeutic antibody, or a protein kinase inhibitor, to the subject in need of such treatment.

### Claim at position 38

60-74. (canceled)

### Claim 75

A method for treating a disorder associated with compromised vasculostasis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by:
or pharmaceutically acceptable salts thereof.
